TICKERNOMICS Sign up
Last Update: 2023-12-23 06:05:55
Intellipharmaceutics International Inc ( IPCI.TO ) https://www.intellipharmaceutics.com
0.06USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
Canada
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
-21.50%
IPCI.TO
SPY
30.72%
-56.90%
IPCI.TO
SPY
112.82%
-72.85%
IPCI.TO
SPY
201.04%
-99.83%
IPCI.TO
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
2.23
1.83
0.01
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.64
2.47
-0.17
-56.74
0.00
-0.26
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-2600.95
-1171.42
-2541.82
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
10.6496
74.39
41.72
1.64
Other Earnings and Cash Flow Stats:
Intellipharmaceutics International Inc ( IPCI.TO ) Net Income TTM ($MM) is -7.56
Intellipharmaceutics International Inc ( IPCI.TO ) Operating Income TTM ($MM) is -7.15
Intellipharmaceutics International Inc ( IPCI.TO ) Owners' Earnings Annual ($MM) is 0.00
Intellipharmaceutics International Inc ( IPCI.TO ) Current Price to Owners' Earnings ratio is 0.00
Intellipharmaceutics International Inc ( IPCI.TO ) EBITDA TTM ($MM) is -6.99
Intellipharmaceutics International Inc ( IPCI.TO ) EBITDA Margin is -2541.82%
Capital Allocation:
Intellipharmaceutics International Inc ( IPCI.TO ) has paid 0.00 dividends per share and bought back -5.0000000015871e-06 million shares in the past 12 months
Intellipharmaceutics International Inc ( IPCI.TO ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
Intellipharmaceutics International Inc ( IPCI.TO ) Interest-bearing Debt ($MM) as of last quarter is 0
Intellipharmaceutics International Inc ( IPCI.TO ) Annual Working Capital Investments ($MM) are -2
Intellipharmaceutics International Inc ( IPCI.TO ) Book Value ($MM) as of last quarter is -13
Intellipharmaceutics International Inc ( IPCI.TO ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Intellipharmaceutics International Inc ( IPCI.TO ) has 0 million in cash on hand as of last quarter
Intellipharmaceutics International Inc ( IPCI.TO ) has 14 million of liabilities due within 12 months, and long term debt 2 as of last quarter
Intellipharmaceutics International Inc ( IPCI.TO ) has 33 common shares outstanding as of last quarter
Intellipharmaceutics International Inc ( IPCI.TO ) has 0 million USD of preferred stock value
Academic Scores:
Intellipharmaceutics International Inc ( IPCI.TO ) Altman Z-Score is -121.26 as of last quarter
Intellipharmaceutics International Inc ( IPCI.TO ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
Intellipharmaceutics International Inc ( IPCI.TO ) largest shareholder is owning shares at 0.00 ($MM) value
(an insider) shares of Intellipharmaceutics International Inc ( IPCI.TO ) for the amount of $ on
1.76% of Intellipharmaceutics International Inc ( IPCI.TO ) is held by insiders, and 11.10% is held by institutions
Intellipharmaceutics International Inc ( IPCI.TO ) went public on 1970-01-01
Other Intellipharmaceutics International Inc ( IPCI.TO ) financial metrics:
FCF:0.96
Unlevered Free Cash Flow:0.00
EPS:-0.23
Operating Margin:-2600.95
Gross Profit Margin:-1171.42
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:58.69
Beta:1.64
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Intellipharmaceutics International Inc ( IPCI.TO ) :
Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.